Helicobacter pylori is a major human pathogen colonizing the gastric mucosa, which can be responsible for severe gastric diseases such as peptic ulcer disease and gastric malignancy. Owing to the multiple mechanisms underlying H. pylori antibiotic resistance, the efficiency of current therapies is declining and constitutes a serious threat to human health. Single drug resistance, multidrug resistance, and hetero resistance are the results of well-studied DNA mutations, interrupting the cellular activity of antibiotics. Impaired regulation of drug uptake and/or efflux, or biofilm and coccoid formation are complex biological processes contributing to H. pylori antibiotic resistance that highly need further elucidation. The resistance and persistence of H. pylori has forced researchers and clinicians to modify the strategies against this recalcitrant pathogen and employ innovative interventions with the goal of its control and eradication.
In addition, the reduction in the effectiveness of current treatments for H. pylori infection obliged clinicians to administrate higher doses of antibiotics or increase treatment duration which, in turn, may result in more serious adverse side effects. These adverse effects highlight the great urgency of broadening the knowledge about drug resistance mechanisms (i.e. underlying single drug and multidrug resistance) and the importance of what could be achieved just by improving diagnostic tools. Thus, further research is required to develop highly efficient therapies and discover novel drug targets to reduce the risk of treatment failure and development of H. pylori-related gastric diseases.
In this Research Topic we welcome articles on the following themes, but not limited to, those listed below:
• Biological attributes driving drug resistance in H. pylori such as DNA mutations, efflux pumps, and biofilm/coccoid formation
• The emergence and spread of drug resistance genes and mechanisms through dysbiosis in gastrointestinal microbiome following H. pylori eradication therapies
• Identification of novel therapeutic interventions to promote H. pylori management and reduce the side effects of current eradication regimens
• Innovative strategies for improving the detection of H. pylori antibiotic resistance profile
• Clinical, translational and epidemiological studies on H. pylori drug resistance and treatment
Helicobacter pylori is a major human pathogen colonizing the gastric mucosa, which can be responsible for severe gastric diseases such as peptic ulcer disease and gastric malignancy. Owing to the multiple mechanisms underlying H. pylori antibiotic resistance, the efficiency of current therapies is declining and constitutes a serious threat to human health. Single drug resistance, multidrug resistance, and hetero resistance are the results of well-studied DNA mutations, interrupting the cellular activity of antibiotics. Impaired regulation of drug uptake and/or efflux, or biofilm and coccoid formation are complex biological processes contributing to H. pylori antibiotic resistance that highly need further elucidation. The resistance and persistence of H. pylori has forced researchers and clinicians to modify the strategies against this recalcitrant pathogen and employ innovative interventions with the goal of its control and eradication.
In addition, the reduction in the effectiveness of current treatments for H. pylori infection obliged clinicians to administrate higher doses of antibiotics or increase treatment duration which, in turn, may result in more serious adverse side effects. These adverse effects highlight the great urgency of broadening the knowledge about drug resistance mechanisms (i.e. underlying single drug and multidrug resistance) and the importance of what could be achieved just by improving diagnostic tools. Thus, further research is required to develop highly efficient therapies and discover novel drug targets to reduce the risk of treatment failure and development of H. pylori-related gastric diseases.
In this Research Topic we welcome articles on the following themes, but not limited to, those listed below:
• Biological attributes driving drug resistance in H. pylori such as DNA mutations, efflux pumps, and biofilm/coccoid formation
• The emergence and spread of drug resistance genes and mechanisms through dysbiosis in gastrointestinal microbiome following H. pylori eradication therapies
• Identification of novel therapeutic interventions to promote H. pylori management and reduce the side effects of current eradication regimens
• Innovative strategies for improving the detection of H. pylori antibiotic resistance profile
• Clinical, translational and epidemiological studies on H. pylori drug resistance and treatment
